Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Enliven Therapeutics announced the launch of a proposed underwritten public offering targeting $250.0 million in gross proceeds from the sale of common stock and pre-funded warrants. The deal includes a 30-day option for underwriters to purchase an additional $37.5 million of common stock.
Key figures
- Deal Value Usd
- 250000000
- Greenshoe amount
- 37500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.